

INDOMETACIN

Trade Name	Ductaclose (Samarth)								
Class	Non steroidal anti –inflammatory (NSAID)								
Mechanism of Action	Reduces cyclo-oxygenase activity and causes decreased prostaglandin synthesis								
Indications	Medical closure of symptomatic Patent Ductus Arteriosus (PDA)								
Contraindications	Duct dependent cardiac lesion Concomitant steroid use ie: hydrocortisone/dexamethasone Pulmonary hypertension Thrombocytopenia platelets < 80 x 10 ⁹ /L, or bleeding Renal failure creatinine > 120 micromol/L, or oliguria (<0.5ml/kg/hr) NEC suspected or confirmed Sensitivity to indomethacin								
Supplied As	Lyophilized white/yellow powder 1mg / ampoule								
Dilution *Two dilution steps required*	Chart for 3 doses and fax to Sterile Pharmacy to dilute and make up 3 doses from a single vial If unable to be drawn up in Sterile Pharmacy <table border="1"> <thead> <tr> <th>Vial</th> <th>Water Added</th> <th>Total Volume</th> <th>Concentration</th> </tr> </thead> <tbody> <tr> <td>1mg</td> <td>2mL</td> <td>2mL</td> <td>0.5mg/mL</td> </tr> </tbody> </table> <p>Then further dilute by taking 1mL (0.5mg) and diluting with 4mL of water to give a final concentration of 0.1mg/mL</p> <p>If the dose volume is <0.5mL then will need to further dilute before infusing via the T34 pump (see T34 protocol)</p>	Vial	Water Added	Total Volume	Concentration	1mg	2mL	2mL	0.5mg/mL
Vial	Water Added	Total Volume	Concentration						
1mg	2mL	2mL	0.5mg/mL						
Dosage	0.2 mg/kg/dose for 3 doses 0.1 mg/kg/dose if creatinine >100micromol/L								
Interval	12 hourly SMO discretion to adjust dosage interval to 24 hourly depending on the clinical picture								
Administration	IV infusion over 30 minutes								

Compatible With	<p>Solutions: dextrose 5%, dextrose 10%, sodium chloride 0.9%, water for injection</p> <p>Terminal Y-site compatibility: furosemide, insulin, nitroprusside, potassium chloride, sodium bicarbonate</p>
Incompatible With	TPN, calcium gluconate, dopamine, dobutamine, gentamicin, tobramycin.
Monitoring	<p>Monitor urine output, serum electrolytes, creatinine and platelet count, assess for GI or prolonged bleeding.</p> <p>Re-echo after the course to assess response</p>
Stability	Discard unused portion immediately
Storage	Room temperature < 30 °C - protect from light
Adverse Reactions	Transient renal dysfunction, hyperkalaemia, hypoglycaemia, hyponatraemia, decreased platelet aggregation, anaemia.
Metabolism	Metabolised by liver, excreted by kidneys - Individual variation in t _{1/2} : 5-90 hours
Comments	<p>If indomethacin causes oliguria, the dosing interval of other renally excreted drugs (eg. gentamicin, vancomycin) may need to be prolonged.</p> <p>Feed intolerance common - may need to withhold feeds.</p> <p>Previously known as Indomethacin</p>
References	<ol style="list-style-type: none"> 1. Trissell Handbook on Injectable Drugs. 10th edition. 2. Waikato Drug manual 1994 3. Neofax online in www.micomedexsolutions.com 4. ADC 1991, 66:55-58 - Prolonged low dose 5. Cochrane Database of Systematic Reviews. Prolonged versus short courses of indomethacin for the treatment of PDA in preterm infants. 2007 Issue 4
Updated By	<p>Dr Peter Schmidt, B Robertshawe October 2004</p> <p>A Lynn, B Robertshawe December 2007</p> <p>A Lynn, B Robertshawe, N Austin February 2008</p> <p>A Lynn, B Robertshawe May 2009 (new pumps), June 2010</p> <p>A Lynn, B Robertshawe Oct 2012 (re-order profile, 2 dilutions)</p> <p>A Lynn, M Wallenstein, B Robertshawe May 2021 SMO consensus</p>